78 results
8-K
ARAV
Aravive Inc
2 Aug 23
Aravive Announces Top-Line Results from Phase 3 AXLerate-OC Study of Batiraxcept in Platinum-Resistant Ovarian Cancer
4:18pm
approach for the assessment of PFS first in the bevacizumab-naïve population and then in the overall cohort of patients. In the bevacizumab-naïve … bevacizumab prior to study entry. The statistical analysis plan called for a hierarchical approach for the assessment of PFS first in the bevacizumab-naïve
8-K
EX-99.1
janwuyfg2 fd
2 Aug 23
Aravive Announces Top-Line Results from Phase 3 AXLerate-OC Study of Batiraxcept in Platinum-Resistant Ovarian Cancer
4:18pm
8-K
rejmzo5
26 May 22
Development of biomarker offers the potential of a first in class targeted therapy in renal cancer
5:26pm
8-K
EX-99.1
myviyf06gt w887567rk
26 May 22
Development of biomarker offers the potential of a first in class targeted therapy in renal cancer
5:26pm
8-K
95oi4d67jd3m0u9nqkh
9 Nov 21
3 of 5 (60%) patients achieved a partial response All 5 patients treated demonstrated tumor decrease from baseline
8:29am
8-K
EX-99.1
0edpmkxtoan mh
9 Nov 21
3 of 5 (60%) patients achieved a partial response All 5 patients treated demonstrated tumor decrease from baseline
8:29am